Related Experiment Videos
Determination of plasma malondialdehyde-like material and its clinical application in stroke patients
Abstract:
Plasma malondialdehyde-like material (MDA-LM) was evaluated in 138 normal subjects and in a group of 57 stroke patients using a modification of the method of Smith et al. (1976). The basal level of MDA-LM in the control group was 35 mumol/l with a range of 22-50 mumol/l. Values above 50 mumol/l were found in 80% of the patients suffering from subarachnoid haemorrhage, in 68% of those with cerebral thrombosis, and in 17% with transient ischaemic attacks. None of the patients with cerebral embolism, intracerebral haematoma, or lacunar infarct had values above 50 mumol/l. Significant statistical differences were found between the control group and all the patients except those with lacunar infarcts.
Insights
Elevated plasma malondialdehyde-like material (MDA-LM) levels indicate increased oxidative stress in stroke patients. This biomarker helps differentiate stroke types, excluding lacunar infarcts.
Area of Science:
- Biochemistry
- Neurology
- Clinical Chemistry
Background:
- Oxidative stress plays a role in cerebrovascular diseases.
- Malondialdehyde-like material (MDA-LM) is a marker of lipid peroxidation.
Purpose of the Study:
- To evaluate plasma MDA-LM levels in stroke patients.
- To determine if MDA-LM can differentiate between stroke subtypes.
Main Methods:
- Plasma MDA-LM was measured in 138 healthy subjects and 57 stroke patients.
- A modified Smith et al. (1976) method was employed.
Main Results:
- Basal MDA-LM in controls was 35 mumol/l (range 22-50 mumol/l).
- Elevated MDA-LM (>50 mumol/l) was observed in 80% of subarachnoid hemorrhage, 68% of cerebral thrombosis, and 17% of transient ischemic attack patients.
- Patients with cerebral embolism, intracerebral hematoma, or lacunar infarct showed no elevated MDA-LM.
Conclusions:
- Plasma MDA-LM levels are significantly elevated in most stroke types compared to controls.
- MDA-LM shows potential as a biomarker for differentiating certain stroke subtypes, particularly excluding lacunar infarcts.